What our committee has said is that if somebody wishes to manufacture a painkiller or an addiction treatment, the minimum standard should at least be that it has to be abuse-deterrent; that is the minimum standard, if you're going to bring them into market.
Ideally, if we, marketing Suboxone, decided that we were going to start to manufacture prescription opioids that could be treated by the very drug that we manufacture, that to me would be wrong. If you talk to the average person, and I've talked to folks.... Mr. Young will know Ada Thompson, from the association of responsible prescribing for opioids. She agrees as well that you cannot allow the double-dipping, because you're essentially allowing volume driving.
If the federal government can look at that when they are doing NOCs, they should have that bare minimum standard of abuse deterrence, but the end goal should be that nobody should be able to do both.